Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CASTLE BIOSCIENCES, INC. reported revenue of $344M, up 3.7% year over year. Operating margin was -12.4% and net margin -7.0%, on a free-cash-flow margin of 8.2% with capital expenditure at 10.5% of revenue. Every figure is computed directly from CSTL's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $344M | -12.4% | -7.0% |
| FY2024 | $332M | 2.6% | 5.5% |
| FY2023 | $220M | -30.9% | -26.1% |
| FY2022 | $137M | -53.2% | -49.0% |
| FY2021 | $94M | -42.6% | -33.3% |
How does CSTL compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AACG · ABSI · ACCS · ACHC · ACM · ADUS
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.